MARKET

IONS

IONS

Ionis Pharmaceuticals
NASDAQ
74.58
+1.04
+1.41%
After Hours: 74.58 0 0.00% 16:04 06/09 EDT
OPEN
74.14
PREV CLOSE
73.54
HIGH
75.79
LOW
73.53
VOLUME
1.57M
TURNOVER
--
52 WEEK HIGH
86.74
52 WEEK LOW
34.78
MARKET CAP
12.33B
P/E (TTM)
-35.4940
1D
5D
1M
3M
1Y
5Y
1D
Fonds de solidarité FTQ joins $20 million CELYSTRA Pharma financing round
PUBT · 6h ago
Ionis Pharmaceuticals director Peter N. Reikes files initial beneficial ownership statement
PUBT · 23h ago
Ionis Pharmaceuticals director Ludwig Hantson files initial beneficial ownership statement
PUBT · 23h ago
Ionis Pharmaceuticals Adds Veteran Leader to Board
TipRanks · 1d ago
Ionis adds former Alexion CEO Ludwig Hantson to board
PUBT · 1d ago
Ionis Pharmaceuticals appoints Hantson to Board of Directors
TipRanks · 1d ago
IONIS ANNOUNCES APPOINTMENT OF LUDWIG HANTSON, PH.D. TO BOARD OF DIRECTORS
Reuters · 1d ago
*Ionis Announces Appointment of Ludwig Hantson to Bd of Directors
Dow Jones · 1d ago
More
About IONS
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.

Webull offers Ionis Pharmaceuticals Inc stock information, including NASDAQ: IONS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IONS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IONS stock methods without spending real money on the virtual paper trading platform.